Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).
1 finding from 1 review
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Large‐for‐gestational age · women with gestational diabetes mellitus
Myo‐inositol showed no clear difference in large‐for‐gestational age compared with placebo (low certainty).
1 finding from 1 review
Induction of labour · women with gestational diabetes mellitus
1 finding from 1 review
Perineal trauma · women with gestational diabetes mellitus
1 finding from 1 review
Postnatal weight retention or return to pre‐pregnancy weight · women with gestational diabetes mellitus
1 finding from 1 review
Postnatal depression · women with gestational diabetes mellitus
1 finding from 1 review
Development of type 2 diabetes · women with gestational diabetes mellitus
1 finding from 1 review
Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
Neonatal hypoglycaemia · women with gestational diabetes mellitus
Myo‐inositol may leads to lower neonatal hypoglycaemia compared with placebo (low certainty).
1 finding from 1 review
Composite of serious neonatal outcomes · women with gestational diabetes mellitus
1 finding from 1 review